SEC Form 4 · accession 0001179110-17-013186
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katherine Parker
Officer — VP of Human Resources
Period of report
Oct 4, 2017
Accepted (ET)
Oct 6, 2017 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 4, 2017 | A | 30,000 | $0.00 | A | 63,109 | D | |
| Common Stock | holding | — | — | — | 1,200 | I | By trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/2 annually over a period of 2 years beginning on October 4, 2018, in the form of one share of common stock for each restricted stock unit.
- F2Includes 1500 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2017.
Remarks
Previous filings included indirect ownership of 1200 shares by spouse trust but are no longer indirectly owned by section 16 officer due to dissolution of marriage.